Works matching IS 11738804 AND DT 2023 AND VI 37 AND IP 5
Results: 11
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 583, doi. 10.1007/s40259-023-00619-0
- By:
- Publication type:
- Article
Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 637, doi. 10.1007/s40259-023-00618-1
- By:
- Publication type:
- Article
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 595, doi. 10.1007/s40259-023-00615-4
- By:
- Publication type:
- Article
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 625, doi. 10.1007/s40259-023-00612-7
- By:
- Publication type:
- Article
Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 649, doi. 10.1007/s40259-023-00611-8
- By:
- Publication type:
- Article
Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 685, doi. 10.1007/s40259-023-00609-2
- By:
- Publication type:
- Article
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 607, doi. 10.1007/s40259-023-00608-3
- By:
- Publication type:
- Article
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 709, doi. 10.1007/s40259-023-00607-4
- By:
- Publication type:
- Article
Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 721, doi. 10.1007/s40259-023-00604-7
- By:
- Publication type:
- Article
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 699, doi. 10.1007/s40259-023-00603-8
- By:
- Publication type:
- Article
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
- Published in:
- BioDrugs, 2023, v. 37, n. 5, p. 675, doi. 10.1007/s40259-023-00601-w
- By:
- Publication type:
- Article